CINECA IRIS Institutional Research Information System

MASI, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.608
AS - Asia 11.447
EU - Europa 8.247
SA - Sud America 1.772
AF - Africa 445
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 10
Totale 44.548
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.929
SG - Singapore 3.845
CN - Cina 3.280
IT - Italia 2.939
HK - Hong Kong 2.078
BR - Brasile 1.502
SE - Svezia 1.211
DE - Germania 785
BG - Bulgaria 753
VN - Vietnam 605
CA - Canada 543
GB - Regno Unito 505
TR - Turchia 442
UA - Ucraina 425
RU - Federazione Russa 409
FI - Finlandia 345
KR - Corea 297
CH - Svizzera 212
IN - India 207
FR - Francia 186
CI - Costa d'Avorio 178
JP - Giappone 130
AT - Austria 119
BD - Bangladesh 110
AR - Argentina 104
NL - Olanda 83
MX - Messico 73
ID - Indonesia 71
IQ - Iraq 70
PL - Polonia 70
PK - Pakistan 56
SN - Senegal 49
ZA - Sudafrica 44
VE - Venezuela 43
ES - Italia 42
SA - Arabia Saudita 40
EC - Ecuador 39
NG - Nigeria 36
MA - Marocco 34
UZ - Uzbekistan 34
BE - Belgio 30
CZ - Repubblica Ceca 22
KE - Kenya 21
CO - Colombia 20
EG - Egitto 20
MY - Malesia 19
PY - Paraguay 19
PH - Filippine 17
AE - Emirati Arabi Uniti 16
BJ - Benin 16
LT - Lituania 16
IL - Israele 15
TN - Tunisia 15
IR - Iran 14
PT - Portogallo 13
UY - Uruguay 13
JO - Giordania 12
AU - Australia 11
CL - Cile 11
IE - Irlanda 11
PE - Perù 11
TW - Taiwan 11
DZ - Algeria 10
NP - Nepal 10
PA - Panama 10
BO - Bolivia 9
RO - Romania 9
EU - Europa 7
GR - Grecia 7
HN - Honduras 7
JM - Giamaica 7
KH - Cambogia 7
NZ - Nuova Zelanda 7
OM - Oman 7
AZ - Azerbaigian 6
BB - Barbados 6
CR - Costa Rica 6
DK - Danimarca 6
DO - Repubblica Dominicana 6
HR - Croazia 6
LB - Libano 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
AL - Albania 5
KZ - Kazakistan 5
LU - Lussemburgo 5
SK - Slovacchia (Repubblica Slovacca) 5
EE - Estonia 4
GA - Gabon 4
HU - Ungheria 4
KG - Kirghizistan 4
LV - Lettonia 4
NO - Norvegia 4
SY - Repubblica araba siriana 4
AO - Angola 3
GT - Guatemala 3
KW - Kuwait 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
Totale 44.493
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.005
Ashburn 2.299
Hong Kong 2.052
Singapore 2.015
Ann Arbor 1.916
Houston 1.486
Fairfield 1.434
Santa Clara 1.278
Chandler 1.206
Milan 1.049
Dallas 1.046
Shanghai 753
Sofia 752
Seattle 668
Jacksonville 597
New York 578
Cambridge 573
Beijing 569
Wilmington 567
Boardman 502
Ottawa 460
Hefei 449
Los Angeles 373
Princeton 311
Lawrence 299
Izmir 284
Seoul 280
Medford 266
Nanjing 263
Serra 243
Bern 199
Dearborn 181
Abidjan 178
Buffalo 158
London 147
Pisa 146
Florence 141
Munich 130
Des Moines 125
Ho Chi Minh City 122
Redondo Beach 122
Rome 122
Istanbul 115
Dong Ket 110
Nanchang 106
São Paulo 106
Düsseldorf 104
Jüchen 102
Tokyo 99
San Diego 93
Vienna 88
Redwood City 84
Cascina 73
Hanoi 68
Ogden 67
Kunming 62
Nuremberg 61
Turku 61
Frankfurt am Main 60
Warsaw 60
Shenyang 58
Boulder 50
Bremen 49
Council Bluffs 49
Dakar 49
Changsha 47
Hebei 46
Lancaster 46
Helsinki 42
Chicago 41
Tianjin 38
Fuzhou 37
Rio de Janeiro 37
Guangzhou 35
Lagos 35
Norwalk 35
Phoenix 34
Belo Horizonte 33
Montreal 32
Brasília 31
The Dalles 31
Dhaka 30
Pune 30
Tashkent 30
San Jose 29
Baghdad 28
Genoa 28
Jiaxing 28
Seacroft 28
Hyderabad 27
Denver 26
Boston 25
Brooklyn 24
Brussels 24
Columbus 24
Hangzhou 24
Toronto 24
Washington 24
Auburn Hills 23
San Francisco 23
Totale 32.217
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 244
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 233
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 224
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 216
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 209
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 208
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 205
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 197
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 194
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 190
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 188
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 187
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 186
Optimal approach to potentially resectable liver metastases from colorectal cancer 185
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 183
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 182
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 182
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 180
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 178
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 178
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 177
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 177
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 176
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 176
Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume 175
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 174
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 172
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 172
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
TAS-102 for the treatment of metastatic colorectal cancer 171
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy 170
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 170
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 170
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 169
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 168
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 168
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 168
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 167
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 167
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 166
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 166
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 165
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 164
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 164
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 164
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 163
Palliative treatment of unresectable metastatic colorectal cancer 162
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 161
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 161
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 161
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 161
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 160
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 159
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 159
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 159
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 159
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 158
Management of peritoneal carcinomatosis with cytoreductive surgery combined with intraperitoneal chemohyperthermia at a novel italian center 157
Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI 156
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 156
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 156
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 155
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 154
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI 154
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 154
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials 154
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 154
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 153
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) 153
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 152
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 152
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 152
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 152
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 151
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line folfoxiri 151
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 151
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 150
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 150
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 150
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 149
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 149
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 148
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. 148
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 148
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 147
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 147
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target 146
CETUXIMAB RECHALLENGE IN METASTATIC COLORECTAL CANCER PATIENTS: HOW TO COME AWAY FROM ACQUIRED RESISTENCE? 146
Optimal strategy to increase the respectability of liver/lung metastases 145
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 145
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). 145
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 145
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.) 144
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 144
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 143
Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 143
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial 143
Totale 16.585
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.646 0 0 0 0 0 261 182 206 240 178 175 404
2021/20222.900 34 186 93 151 550 470 41 112 117 119 211 816
2022/20233.584 428 365 218 293 456 507 37 271 685 21 264 39
2023/20244.190 521 535 530 324 582 614 285 150 78 85 141 345
2024/202511.188 113 428 165 503 886 1.316 765 578 1.140 1.428 1.359 2.507
2025/20267.654 834 1.620 1.391 1.162 1.325 1.322 0 0 0 0 0 0
Totale 45.235